Article Text

Download PDFPDF

BAS/BSCR poster abstract
BAS/BSCR42 Effect of p38-α gene silencing on cytokine and matrix metalloproteinase expression by human cardiac myofibroblasts
  1. J K Sinfield,
  2. A Das,
  3. K E Porter,
  4. N A Turner
  1. Division of Cardiovascular and Neuronal Remodelling, Multidisciplinary Cardiovascular Research Centre (MCRC), University of Leeds, Leeds, UK


Cardiac myofibroblasts (CMF) have a key role in the remodelling of the heart that occurs following a myocardial infarction. This remodelling can be initiated by increased myocardial levels of proinflammatory cytokines (eg, interleukin (IL)-1), that can stimulate cardiac myofibroblasts to express other proinflammatory cytokines and matrix metalloproteinases (MMPs). The p38 mitogen-activated protein kinase (MAPK) signalling pathway is also known to be detrimental in the myocardial remodelling process. There are four known p38 MAPK subtypes (α, β, γ and δ) and CMF express the α, γ and δ subtypes. The aim of this study was to determine the role of individual p38 subtypes in mediating IL-1-induced increases in proinflammatory cytokine and MMP expression in cultured cardiac myofibroblasts from different patients. Pharmacological inhibitors of p38-α/β (SB203580) and p38-α/β/γ/δ (BIRB-0796) inhibited IL-1-induced IL-6 and MMP-3 mRNA expression to similar extents, suggesting a key role for p38-α. Neither inhibitor affected IL-1-induced IL-1β or MMP-9 mRNA levels. Gene silencing with p38-α siRNA oligonucleotides selectively reduced p38-α protein expression by >95% and prevented consequent phosphorylation of the downstream substrate MAPKAPK2. However, p38-α silencing did not markedly inhibit phosphorylation of the MAPKAPK2 substrate HSP27. Furthermore, p38-α gene silencing did not reduce IL-1-induced expression of IL-6 or MMP-3 (or IL-1β or MMP-9). Thus, in contrast to results with pharmacological p38 MAPK inhibitors, gene silencing of p38-α in human cardiac myofibroblasts did not inhibit IL-1-induced IL-6 and MMP-3 expression. This raises interesting questions about pharmacological versus molecular strategies for inhibiting p38 MAPK subtypes in the remodelling heart.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding Funded by a British Heart Foundation project grant.